Regeneron Pharmaceuticals (REGN) Return on Invested Capital (2017 - 2026)

Regeneron Pharmaceuticals' Return on Invested Capital history runs 8 years deep, the most recent figure standing at 0.04% for Q1 2026.

• On a quarterly basis, Return on Invested Capital changed 0.0% year-over-year to 0.04% in Q1 2026; TTM through Mar 2026 was 0.04%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 0.04%, down 1.0% from the prior year.
• Return on Invested Capital climbed to 0.04% in Q1 2026 per REGN's latest filing, from 0.04% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.07% in Q1 2022 and bottomed at 0.01% in Q4 2022.
• The 5-year median for Return on Invested Capital is 0.05% (2025), against an average of 0.04%.
• Biggest YoY gain for Return on Invested Capital was 6 bps in 2022; the steepest drop was 9 bps in 2022.
• Year by year, Return on Invested Capital stood at 0.01% in 2022, then soared by 260 bps to 0.05% in 2023, then retreated by 3 bps to 0.05% in 2024, then slipped by 16 bps to 0.04% in 2025, then increased by 1 bps to 0.04% in 2026.
• Per Business Quant, the three latest REGN Return on Invested Capital figures stand at 0.04% (Q1 2026), 0.04% (Q4 2025), and 0.05% (Q3 2025).